PTC Therapeutics | PTCT - Cash And Equivalent



PTC Therapeutics reported $1.02B in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 762M 80.42M Jun/2025
Alnylam Pharmaceuticals USD 1.11B 94.03M Jun/2025
Amgen USD 8.03B 782M Jun/2025
Biogen USD 2.76B 160.5M Jun/2025
BioMarin Pharmaceutical USD 1.21B 601.78M Jun/2025
Cytokinetics USD 74.94M 863.28M Jun/2025
Daiichi Sankyo JPY 639.84B 42.31B Mar/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Incyte USD 2.42B 13.08M Jun/2025
Ionis Pharmaceuticals USD 297.3M 33.11M Jun/2025
Ironwood Pharmaceuticals USD 88.56M 348K Dec/2024
Novartis USD 6.66B 410M Jun/2025
Pfizer USD 1.64B 208M Jun/2025
PTC Therapeutics USD 1.02B 1.01B Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sarepta Therapeutics USD 510.6M 269.73M Jun/2025
TG Therapeutics USD 278.86M 146.72M Jun/2025
Ultragenyx Pharmaceutical USD 166.11M 396.9M Jun/2025
Vertex Pharmaceuticals USD 6.38B 1.71B Jun/2025
Xencor USD 44.44M 4.77M Jun/2025